Clinical Trial

Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A phase III clinical study to evaluate the efficacy and safety of a humanized MG-K10 mab injection in subjects with prurigo nodularis.administered every 4 weeks for 56 weeks.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-12.
Status change: Not Yet Recruiting → Recruiting 2025-04-15
Trial Details
NCT Number NCT06779136
Lead Sponsor Shanghai Mabgeek Biotech.Co.Ltd
Conditions Prurigo Nodularis
Enrollment 160 participants
Start Date 2025-02-26
Primary Completion 2026-08 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2025-04-18